BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9862871)

  • 1. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance.
    Pichoud C; Seignères B; Wang Z; Trépo C; Zoulim F
    Hepatology; 1999 Jan; 29(1):230-7. PubMed ID: 9862871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.
    Delaney WE; Yang H; Westland CE; Das K; Arnold E; Gibbs CS; Miller MD; Xiong S
    J Virol; 2003 Nov; 77(21):11833-41. PubMed ID: 14557667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of hepatitis B virus variants resistant to lamivudine and famciclovir among randomly selected chronic carriers from Spain.
    León P; Pozo F; Echevarría JM
    Enferm Infecc Microbiol Clin; 2004 Mar; 22(3):133-7. PubMed ID: 14987532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance.
    Xiong X; Yang H; Westland CE; Zou R; Gibbs CS
    Hepatology; 2000 Jan; 31(1):219-24. PubMed ID: 10613749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective.
    Melegari M; Scaglioni PP; Wands JR
    Hepatology; 1998 Feb; 27(2):628-33. PubMed ID: 9462667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy.
    Mutimer D; Pillay D; Cook P; Ratcliffe D; O'Donnell K; Dowling D; Shaw J; Elias E; Cane PA
    J Infect Dis; 2000 Feb; 181(2):713-6. PubMed ID: 10669360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B.
    Seignères B; Pichoud C; Ahmed SS; Hantz O; Trépo C; Zoulim F
    J Infect Dis; 2000 Apr; 181(4):1221-33. PubMed ID: 10762559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss.
    de Man RA; Bartholomeusz AI; Niesters HG; Zondervan PE; Locarnini SA
    J Hepatol; 1998 Oct; 29(4):669-75. PubMed ID: 9824278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene.
    Torresi J; Earnest-Silveira L; Civitico G; Walters TE; Lewin SR; Fyfe J; Locarnini SA; Manns M; Trautwein C; Bock TC
    Virology; 2002 Jul; 299(1):88-99. PubMed ID: 12167344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation.
    Tillmann HL; Trautwein C; Bock T; Böker KH; Jäckel E; Glowienka M; Oldhafer K; Bruns I; Gauthier J; Condreay LD; Raab HR; Manns MP
    Hepatology; 1999 Jul; 30(1):244-56. PubMed ID: 10385663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains.
    Amini-Bavil-Olyaee S; Herbers U; Sheldon J; Luedde T; Trautwein C; Tacke F
    Hepatology; 2009 Apr; 49(4):1158-65. PubMed ID: 19263474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation.
    Aye TT; Bartholomeusz A; Shaw T; Bowden S; Breschkin A; McMillan J; Angus P; Locarnini S
    J Hepatol; 1997 May; 26(5):1148-53. PubMed ID: 9186847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.
    Delaney WE; Edwards R; Colledge D; Shaw T; Torresi J; Miller TG; Isom HC; Bock CT; Manns MP; Trautwein C; Locarnini S
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1705-13. PubMed ID: 11353615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine.
    Tatti KM; Korba BE; Stang HL; Peek S; Gerin JL; Tennant BC; Schinazi RF
    Antiviral Res; 2002 Jul; 55(1):141-50. PubMed ID: 12076758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening and identification of a novel adefovir dipivoxil resistance associated mutation, rtN236V, of HBV from a large cohort of HBV-infected patients.
    Liu Y; Liu W; Li X; Xu Z; Wang X; Li C; Chen L; Xin S; Xu D
    Antivir Ther; 2014; 19(6):551-8. PubMed ID: 24710668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. rtE218G, a novel hepatitis B virus mutation with resistance to adefovir dipivoxil in patients with chronic hepatitis B.
    Liu LJ; Wang JH; Du SC; Tian JH; Yang RF; Wei L
    J Viral Hepat; 2010 Mar; 17 Suppl 1():66-72. PubMed ID: 20586936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).
    Das K; Xiong X; Yang H; Westland CE; Gibbs CS; Sarafianos SG; Arnold E
    J Virol; 2001 May; 75(10):4771-9. PubMed ID: 11312349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure.
    Günther S; von Breunig F; Santantonio T; Jung MC; Gaeta GB; Fischer L; Sterneck M; Will H
    J Hepatol; 1999 May; 30(5):749-54. PubMed ID: 10365797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome.
    Amini-Bavil-Olyaee S; Herbers U; Mohebbi SR; Sabahi F; Zali MR; Luedde T; Trautwein C; Tacke F
    J Hepatol; 2009 Oct; 51(4):647-54. PubMed ID: 19586679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.